Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 117,872 shares at $621.11 ($72.0M) on 2022-08-05, disclosed to the SEC on 2022-08-08.
Open-market sale of $72.0M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 335 | $0 | 0.0% |
| 2 | $613.00 | 71,218 | $43.7M | 60.6% |
| 3 | $606.78 | 176 | $107K | 0.1% |
| 4 | $606.78 | 176 | $107K | 0.1% |
| 5 | $607.47 | 724 | $440K | 0.6% |
| 6 | $607.47 | 724 |
| $440K |
| 0.6% |
| 7 | $608.70 | 610 | $371K | 0.5% |
| 8 | $609.62 | 3,044 | $1.9M | 2.6% |
| 9 | $609.62 | 3,044 | $1.9M | 2.6% |
| 10 | $610.49 | 3,931 | $2.4M | 3.3% |
| 11 | $610.49 | 3,931 | $2.4M | 3.3% |
| 12 | $611.44 | 2,022 | $1.2M | 1.7% |
| 13 | $611.44 | 2,022 | $1.2M | 1.7% |
| 14 | $612.43 | 2,076 | $1.3M | 1.8% |
| 15 | $612.43 | 2,076 | $1.3M | 1.8% |
| 16 | $613.49 | 3,218 | $2.0M | 2.7% |
| 17 | $613.49 | 3,218 | $2.0M | 2.7% |
| 18 | $614.35 | 4,112 | $2.5M | 3.5% |
| 19 | $614.35 | 4,112 | $2.5M | 3.5% |
| 20 | $615.49 | 1,610 | $991K | 1.4% |
| 21 | $615.49 | 1,610 | $991K | 1.4% |
| 22 | $616.40 | 535 | $330K | 0.5% |
| 23 | $617.43 | 424 | $262K | 0.4% |
| 24 | $617.43 | 424 | $262K | 0.4% |
| 25 | $618.27 | 521 | $322K | 0.4% |
| 26 | $618.27 | 521 | $322K | 0.4% |
| 27 | $619.64 | 502 | $311K | 0.4% |
| 28 | $619.64 | 502 | $311K | 0.4% |
| 29 | $620.11 | 177 | $110K | 0.2% |
| 30 | $620.11 | 177 | $110K | 0.2% |
| 31 | $621.11 | 100 | $62K | 0.1% |
| Total | $611.10 avg | 117,872 | $72.0M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |
| REGN | SELL | 2020-05-11 | $5.9M | — | Filing → |